Slide 1: 1H25 Financial Results Presentation (ASX Announcement)
ASX Announcement 1H25 Financial Results Presentation 26 February 2025 McPherson’s Limited (ASX:MCP) announces that the results for the half year ended 31 December 2024 (1H25) will be presented at a webcast hosted by the Chief Executive Officer and Managing Director – Brett Charlton and Chief Financi
Slide 2: 1H25 Financial Results Presentation
For personal use only 1H25 Financial Results Presentation 26 February 2025
Slide 3: Disclaimer
Disclaimer The following provisions apply to this presentation. Please consider its contents carefully. Currency of information Historical information The information contained in this presentation is current as at the date of this presentation or Past performance information in this presentation is
Slide 4: Agenda
BRETT CHARLTON For personal use only Chief Executive Officer and Managing Director 01 Introduction & Strategy Brett Charlton Agenda 02 Financial Results Mark Sherwin 03 2H25 Priorities & Summary Brett Charlton MARK SHERWIN Chief Financial Officer 3
Slide 5: Introduction & Strategy
For personal use only Introduction & Strategy Brett Charlton
Slide 6: 1H25 Results
1H25 Results Steady progress on transformation, with result yet to reflect new operating model For personal use only REVENUE1 CORE BRAND REVENUE UNDERLYING EBITDA1, 2 • Solid result in a demanding period $70.7m $62.5m $2.0m • Sales from continuing operations includes impact of exit from non- strateg
Slide 7: Core Brand Performance
Core Brand Performance Four out of five core brands in growth with demonstrated share gains Sales Category MCP Brand 1H25 Revenue Commentary Performance1 Performance2 Performance2 For personal use only • Positive performance in major grocery & pharmacy driven by increased ranging and launch of new p
Slide 8: Transformation Roadmap: Progress to Date
Transformation Roadmap: Progress to Date Clear plan to unlock value For personal use only 1H24 2H24 1H25 • November 2023: strategy re-set • June 2024: divestment of Multix • Route to market review • Priority during 1H25 completed has been route to • Clear plan to unlock value • Identified potential
Slide 9: Transformation Update: New route to market
Transformation Update New route to market with third-party warehousing and pharmacy wholesalers Current model: direct to store • Signed agreements with: For personal use only ‒ Excel Logistics: Kingsgrove warehouse PHARMACIES sublease1 and warehousing of McPherson’s HEALTH STORES brands for all chan
Slide 10: 1H25 Financial Results
For personal use only 1H25 Financial Results Mark Sherwin
Slide 11: Summary Financials for Continuing Operations
Summary Financials for Continuing Operations Focus remains on driving performance in core brands All figures in $m 1H25 1H24 $ Var % Var • Revenue decline of $5.8 million reflects: Revenue1 70.7 76.5 (5.8) (7.6%) For personal use only ‒ Exit of non-strategic lower margin Expenses brands Sugar Baby a
Slide 12: Summary Financials by Business Unit
Summary Financials by Business Unit Encouraging core brand performance in Australia and New Zealand Australia and New Zealand Australia and New Zealand For personal use only • Sales decline of $4.3 million largely reflects decision to exit REVENUE1 UNDERLYING EBITDA1, 2 non-strategic brands (Sugar B
Slide 13: Underlying EBITDA Bridge
Underlying EBITDA Bridge Brand investment weighted to 1H25 to support momentum in core brands Underlying EBITDA • Contribution from core brands reflects: For personal use only ($m) ‒ Sales decline of $1.3 million, driven by (5.0) performance of Dr LeWinn’s chiefly in the International business 7.0 ‒
Slide 14: Net Cash Bridge
Net Cash Bridge Strong net cash position to fund transformation initiatives Net Cash • Operating cash flows of $1.8 million with For personal use only ($m) cash conversion of 137%1 (1H24: 130%) • Working capital unwind of $1.1 million 1.6 (0.9) following sale of Multix 1.1 (2.3) • Working capital mo
Slide 15: Transformation Update: Fixed to variable cost model
Transformation Update Transition from majority fixed to variable cost route to market model Annual Incremental For personal use only Underlying EBIT1 1.6 • Sub-lease of Kingsgrove warehouse from 1 March 2025 to end of head lease in June 2027 • Employee cost savings from exit of warehouse and inhouse
Slide 16: 2H25 Priorities & Summary
For personal use only 2H25 Priorities & Summary Brett Charlton
Slide 17: Transformation Roadmap: Looking Ahead
Transformation Roadmap: Looking Ahead Focused on the logical steps to effect transformation For personal use only FY24 1H25 2H25 FY26 • November 2023: strategy re-set • Route to market review completed • Implement new route to market and • New, simplified operating model fully • June 2024: divestmen
Slide 18: 2H25 Priorities and Outlook
2H25 Priorities and Outlook Priority is new operating model For personal use only • Relentless focus on delivering on transformation of the business • Priority for 2H25 is implementation of the new operating model – pathway to unlocking significant residual cost post-Multix divestment • Year-to-date
Slide 19: For personal use only
| use only -Or persona MN © Qo > Health Wellness Beauty
Slide 20: Appendix
For personal use only Appendix
Slide 21: Reconciliation of underlying EBITDA to NPAT
Appendix 1 Reconciliation of underlying EBITDA to NPAT $’000 1H25 1H24 For personal use only Continuing Discontinued Continuing Discontinued Total Total Operations Operations Operations Operations Underlying EBITDA 2,019 884 2,903 7,044 2,107 9,151 Depreciation and amortisation expense (3,195) - (3,